AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Ensysce Biosciences, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00JFF4183
0.47▼ 0.04 (-7.93%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
0.51
Day's Range
0.47 – 0.52
52-Week Range
0.23 – 2.26
Volume
236.5K
Avg Volume
497.7K
Share Statistics
Shares Outstanding
Employees
10
Exchange
XNAS
Listed
2021-07-01
Share count as of August 12, 2026

Ensysce Biosciences, Inc. Common Stock (ENSC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Ensysce Biosciences, Inc. Common Stock (ENSC)
What is Ensysce Biosciences, Inc. Common Stock's Market Cap?
Ensysce Biosciences, Inc. Common Stock's Market Cap is $9.2M, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's Enterprise Value?
Ensysce Biosciences, Inc. Common Stock's Enterprise Value is $8.5M, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's Price / Sales?
Ensysce Biosciences, Inc. Common Stock's Price / Sales is 2.0×, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's EV / Revenue?
Ensysce Biosciences, Inc. Common Stock's EV / Revenue is 1.9×, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's EV / EBITDA?
Ensysce Biosciences, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's Revenue (TTM)?
Ensysce Biosciences, Inc. Common Stock's Revenue (TTM) is $4.5M, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's Net Income (TTM)?
Ensysce Biosciences, Inc. Common Stock's Net Income (TTM) is -$12.6M, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's EBITDA?
Ensysce Biosciences, Inc. Common Stock's EBITDA is -$12.6M, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's Diluted EPS (TTM)?
Ensysce Biosciences, Inc. Common Stock's Diluted EPS (TTM) is -0.65, based on as-reported figures from SEC (XBRL) filings.
What is Ensysce Biosciences, Inc. Common Stock's EBITDA Margin?
Ensysce Biosciences, Inc. Common Stock's EBITDA Margin is -280.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ENSCAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-15.1%-27.2%+44.4%-85.6%
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
% of revenue321.3%470.7%247.8%858.7%
Loss from operations
% of revenue-221.3%-370.7%-147.8%-758.7%
Other income (expense):
Change in fair value of liability classified warrants——
Interest expense, net
Non-Operating Income (Expense)
Total other income (expense), net
Net loss
% of revenue-220.8%-370.1%-147.0%-756.3%
Net Income Attributable to Noncontrolling Interest—
Deemed dividend related to warrants down round provision————
Net loss attributable to common stockholders
Earnings Per Share (Basic)
Earnings Per Share (Diluted)